Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.69 |
| ▸ | DAO | P14920 | 1/20 | 0.64 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 3/20 | 0.48 |
| ▸ | GABRD | O14764 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914985 | 1.00 | PGR (0.69) | PGRDAOPSMB8MAOBLMNA | |
| SCHEMBL3066593 | 0.85 | LMNA (0.57) | PGRDAOPSMB8MAOBLMNA | |
| SCHEMBL6540944 | 0.82 | PGR (1.00) | PGRDAOPSMB8MAOBLMNA | |
| SCHEMBL9395750 | 0.82 | GRIA1 (0.65) | PGRDAOPSMB8MAOBGABRP | |
| SCHEMBL29859942 | 0.79 | LMNA (0.58) | PGRDAOMAOBLMNAMEN1 | |
| SCHEMBL2522765 | 0.79 | LMNA (0.58) | PGRDAOMAOBLMNAMEN1 | |
| SCHEMBL7220155 | 0.79 | DAO (0.66) | PGRDAOMAOBLMNAMEN1 | |
| SCHEMBL24808382 | 0.79 | MAT2A (0.49) | PGRDAOPSMB8MAOBLMNA | |
| SCHEMBL16997516 | 0.79 | DAO (0.60) | PGRDAOPSMB8MAOBLMNA | |
| SCHEMBL9919007 | 0.79 | CA9 (0.66) | PGRLMNAMEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20230116602-A1 | MCL1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| WO-2022216946-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-4038072-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114746428-A | MCL1 inhibitor and application thereof | 加利福尼亚技术学院 | 2022-07-12 | — | — | CN | disclosed |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | BEBETTER MED INC. (CN) | 2022-03-08 | — | — | US | disclosed |
| WO-2021067827-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3345900-A1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | PGR 1522/4885DAO 1342/4885PSMB8 3311/4885 |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | PGR 1522/4885DAO 1342/4885PSMB8 3311/4885 |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | EGFR, ERBB2, KRAS | PGR 1522/4885DAO 1342/4885PSMB8 3311/4885 |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | PGR 2241/4885DAO 3613/4885PSMB8 2513/4885 |
| US-20230116602-A1 | MCL1 INHIBITORS AND USES THEREOF | MCL1, BCL2L1, BCL2L11 | PGR 3520/4885DAO 4677/4885PSMB8 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.